Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
about
Multigene assays and molecular markers in breast cancer: systematic review of health economic analysesThe impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisBioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trialProgress in the clinical detection of heterogeneity in breast cancerRespective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinomaTowards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.A priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative UltrasoundExome analysis reveals differentially mutated gene signatures of stage, grade and subtype in breast cancers.Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.Three methods for optimization of cross-laboratory and cross-platform microarray expression data.Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysisAlzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications.Exploiting cancer genomics in pet animals to gain advantage for personalized medicine decisions.Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancerTumor gene expression profiling in women with breast cancer. Test category: prognostic.Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.Breast cancer prognostic classification in the molecular era: the role of histological grade.Accuracy validation of adjuvant! online in Taiwanese breast cancer patients--a 10-year analysis.Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.Personalizing health care: feasibility and future implications.US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsThe clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea.Review of the clinical studies using the 21-gene assay.Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence scorePartial PTEN deletion is linked to poor prognosis in breast cancerProspective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH StudyCancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care.Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer8p deletion is strongly linked to poor prognosis in breast cancer.Subtype-specific CpG island shore methylation and mutation patterns in 30 breast cancer cell lines.Personalized medicine in breast cancer: a systematic review.Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation
P2860
Q26825362-AD4C1FD0-7CC1-403F-8ED9-33F5E1C7AF0EQ26861418-ADF7088D-C8C5-41DC-BB75-4DF06E1951BEQ27015838-58351E5C-55FA-4150-8EEC-774B4ABAAA7DQ28079224-61559DFC-306C-4393-8F81-B41A3EE72D18Q28730529-F48A4D54-0428-4451-A85B-AD5C23527F4DQ30252422-DA2CAFE3-DB41-46E9-86C1-5DF5A01F1629Q30358741-BA0B1904-1273-41DF-893C-D2AC3C45C6FEQ30372977-70BE3FFB-71D7-40A5-AD7F-4D71A0FAFB64Q30378787-2D8309B2-D983-4256-8D89-C1043BC6A690Q30543788-962B217F-89FE-4E5A-B81D-82E1BD22A095Q31101528-9FBA87C8-AD54-442F-9C0A-7C505B71FAD5Q31111559-A249B8FF-3D07-4E40-B2ED-5C543F241F93Q33599906-7BBB9059-187B-469F-9542-0EAB63A767B5Q33736582-D67BCA83-6681-4203-AEBC-B9ED0153075EQ33917501-B4883E6E-39B9-4FB7-B110-9480D96DA245Q34022200-C6B6F932-E80F-47B0-8324-B86CE0A2E16AQ34130881-F5EF00E6-ED30-45A1-BCAD-BB40AF27441EQ34171119-D74255AE-2EDB-483E-B870-85C5C2C49EBFQ34173440-C162EEA5-BC5E-4EB9-AFC4-43762B19E685Q34416758-6EB84936-43F3-4372-A32D-4EE257B0EA07Q34431985-5DAB8AAC-9295-42FB-A17A-98B31A32B6E8Q34638067-05E6B329-479C-4CE3-9F0D-1AF230AFC40DQ34938911-F3524BF5-A5F4-4F9F-AEDF-8B7EE5AF7AA3Q34974208-FE14139A-6319-498A-85EC-86C8E89F8B8DQ35008290-678112BF-790A-432D-973C-8D498A591368Q35430076-EAD08056-DBCA-4152-9D89-70DB40860B46Q35584053-7BBFA136-EFD8-4F4A-BF87-D93098CE2326Q35584364-7B64F9C2-3C38-4D07-B70D-D33C40A83F05Q35870069-3B7E9D4B-B11C-46BA-A8C3-3CEF13C00BAFQ35915708-7828C687-0CE3-46A0-9F84-999D3E6AA775Q35999625-DC4177BD-2513-4A46-9B61-1B67343A8BD4Q36055953-5156CD48-864C-4C77-AA32-8A80071B43CCQ36097503-2C808EC7-05E0-47ED-A6A0-67ABCB6C0527Q36214952-52E7E05C-6204-4062-A6F6-353C8A759238Q36268784-7FC34245-F2C7-41B1-9E9D-957704382A18Q36310182-2F596775-CAEE-4B56-B9EA-B048DB36851EQ36339076-CFF4C7DA-EE28-470B-BEF0-CD583B2DD599Q36371617-E387AC0B-9FD3-4D08-A670-287B63E42BBCQ36424052-7A5B475E-6434-48CD-B352-50747788A4ACQ36557305-A503473A-F7AC-46AE-800B-C2C2E4FE80D1
P2860
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Economic analysis of targeting ...... ve, early-stage breast cancer.
@ast
Economic analysis of targeting ...... ve, early-stage breast cancer.
@en
type
label
Economic analysis of targeting ...... ve, early-stage breast cancer.
@ast
Economic analysis of targeting ...... ve, early-stage breast cancer.
@en
prefLabel
Economic analysis of targeting ...... ve, early-stage breast cancer.
@ast
Economic analysis of targeting ...... ve, early-stage breast cancer.
@en
P2093
P1476
Economic analysis of targeting ...... ive, early-stage breast cancer
@en
P2093
Gary H Lyman
John Hornberger
Leon E Cosler
P304
P577
2005-05-01T00:00:00Z